Mutual of America Capital Management LLC Reduces Holdings in LivaNova PLC (NASDAQ:LIVN)

Mutual of America Capital Management LLC lowered its position in LivaNova PLC (NASDAQ:LIVN) by 5.4% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 29,347 shares of the company’s stock after selling 1,659 shares during the period. Mutual of America Capital Management LLC’s holdings in LivaNova were worth $1,542,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in LIVN. Driehaus Capital Management LLC lifted its stake in shares of LivaNova by 64.7% in the second quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company’s stock worth $29,824,000 after buying an additional 213,749 shares in the last quarter. Perceptive Advisors LLC raised its holdings in LivaNova by 48.5% in the 2nd quarter. Perceptive Advisors LLC now owns 444,000 shares of the company’s stock valued at $24,340,000 after acquiring an additional 145,000 shares during the last quarter. Great Lakes Advisors LLC purchased a new position in LivaNova in the 2nd quarter worth approximately $16,614,000. Price T Rowe Associates Inc. MD boosted its holdings in shares of LivaNova by 6.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 31,021 shares of the company’s stock worth $1,736,000 after purchasing an additional 1,980 shares during the last quarter. Finally, Cornercap Investment Counsel Inc. purchased a new stake in shares of LivaNova in the second quarter valued at approximately $1,103,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on LIVN. StockNews.com downgraded LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 16th. Baird R W upgraded LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. The Goldman Sachs Group started coverage on shares of LivaNova in a report on Friday, October 4th. They issued a “buy” rating and a $65.00 price objective for the company. Mizuho cut their price objective on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, October 31st. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $75.00 target price on shares of LivaNova in a report on Monday. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, LivaNova currently has a consensus rating of “Buy” and an average target price of $69.17.

LivaNova Stock Up 0.8 %

Shares of NASDAQ:LIVN opened at $51.75 on Tuesday. The company has a market capitalization of $2.81 billion, a price-to-earnings ratio of 123.21 and a beta of 1.01. LivaNova PLC has a 12-month low of $42.75 and a 12-month high of $64.47. The business has a 50-day moving average price of $52.19 and a 200 day moving average price of $52.38. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.